Ramsay Santé
Perrine Lazian Dauvergne has a diverse work experience spanning various companies and roles. Perrine started their career as a Senior Audit at Deloitte in 2001 and progressed to become a Manager before leaving in 2007. Perrine then joined ResMed as a Financial Analyst from 2007 to 2008. After that, they worked at Unilabs in various positions, including Consolidation and Financial Reporting Manager, Head of Group Accounting, and Finance Transformation Director. Perrine also served as Deputy CFO at Swiss Risk & Care from 2021 to 2022. Currently, they are working as a Financial Director at Ramsay Santé, where they play a key role in leading finance for a group of private hospitals and clinics. Their responsibilities include improving EBITDA and cash generation, enhancing processes, and collaborating with key stakeholders for business partnership.
Perrine Lazian Dauvergne completed their education with a Master's Degree in Finance from KEDGE Business School, where they studied from 1998 to 2001. Additionally, they attended PWC Academy in 2010, specializing in the study of IFRS (International Financial Reporting Standards).
This person is not in any offices
Ramsay Santé
1 followers
After the acquisition of the Capio Group in 2018, Ramsay Santé has become Europe's leading private hospital and primary care companies. The group now has 36,000 employees and works with nearly 8,600 private practitioners. Present in 5 countries, France, Sweden, Norway, Denmark and Italy, the group treats more than 7 million patients per year in its 350 establishments. In hospitalization, Ramsay Santé offers almost all medical and surgical treatments in three business lines: Medicine-Surgery-Obstetrics (MCO), Follow-up and Rehabilitation Care (SSR) and Mental Health. Wherever it is present, the group participates in public health service missions and in the health network of the country, as in Sweden where the group has more than a hundred local health centres. The quality and safety of care is the group's priority in all the countries where it operates. This is why the group is today one of the references in modern medicine, especially in ambulatory surgery and enhanced recovery after surgery (ARS). The group also invests more than €200 million every year in its establishments, whether in new surgical and imaging technologies, or in the construction and modernisation of establishments. It also innovates at the service of patients with new digital tools and by developing its organisations to improve the efficiency of care.